Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy

What you'll learn

Course overview

Hereditary amyloid transthyretin (ATTR) amyloidosis is a progressively debilitating disease caused by the buildup of variant transthyretin proteins in amyloid deposits in the heart, nerves, and digestive system. Symptoms of ATTR amyloidosis with cardiomyopathy (ATTR-CM) overlap with those of other more commonly recognized cardiac diseases, leading to misdiagnosis. As ATTR is now a treatable disease due to recent advances, it is crucial for members of the interdisciplinary care team to remain up to date on genetic testing and diagnostic modalities to improve early identification for early diagnosis and optimal treatment selection (American Heart Association, 2024; Nativi-Nicolau et al, 2021). This activity, presented by Mathew Maurer, MD, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will explore strategies for increasing detection and improving outcomes in patients with hereditary ATTR-CM.